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Abstract We have previously shown that insulin alters the renal 
metabolism of 25-hydroxyvitamin D. To examine the effect of 
insulin on vitamin D metabolism in bone, we have used UMR-106 
osteoblast-like cells to study the regulation of 25(OH)D3-24- 
hydroxylase (24-hydroxylase) expression by insulin. The 24- 
hydroxylase is an important enzyme in degrading 1,25-dihy- 
droxyvitamin D3 (1,25(OH)2D) in target tissues. Insulin alone 
had no effect on mRNA levels of the cytochrome P450 
component (CYP24) of the 24-hydroxylase or on 24-hydroxylase 
activity itself in UMR cells. However, insulin increased the 
capacity of parathyroid hormone (PTH) to elevate CYP24 
mRNA levels by 3-4-fold and to increase 24-hydroxylase activity 
by 2-fold in the presence of 1,25(OH)zD. Insulin increased the 
maximal responsiveness of UMR cells to PTH without altering 
their sensitivity. The action of insulin required the presence of 
1,25(OH)2D and was partly dependent on new protein synthesis. 
Insulin-like growth factor 1 also potentiated the effects of PTH. 
This marked stimulation of the 24-hydroxylase by PTH and 
insulin may serve to regulate 1,25(OH)2D action and/or to 
produce 24,25-dihydroxyvitumin D in bone cells. 
and subsequent insulin administration markedly alter renal 
1-hydroxylase and 24-hydroxylase activity [12]. In diabetic 
rats, the 1-hydroxylase activity is decreased, and the 24-hy- 
droxylase activity is increased compared to non-diabetic rats. 
Insulin administration increases 1-hydroxylase activity and 
decreases 24-hydroxylase activity in the kidney. Insulin ap- 
pears to work by modulating the action of PTH [13]. 
In addition to the kidney, insulin may also have effects on 
vitamin D metabolism in bone cells. To examine this possibil- 
ity, we have studied the effect of insulin on the expression of 
the 24-hydroxylase in UMR-106 osteoblast-like c lls. The pur- 
pose of this study was to determine if insulin alone or in 
combination with 1,25(OH)2D and PTH had an effect on 
24-hydroxylase expression. We measured the effect of these 
hormones on mRNA levels of the cytochrome P450 compo- 
nent of the 24-hydroxylase (CYP24) and also on 24-hydrox- 
ylase enzymatic activity. 
2. Materials and methods 
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1. Introduction 
The active form of vitamin D, 1,25-dihydroxyvitamin D3 
(1,25(OH)2D), is synthesized primarily in the kidney by the 
renal l-hydroxylase [1-5]. The 1,25(OH)2D acts on its major 
target tissues such as intestine, kidney, and bone to regulate 
calcium and phosphate homeostasis [2]. In these tissues, 
1,25(OH)2D is further hydroxylated by the 24-hydroxylase. 
Hydroxylation in the 24-position is thought to be the first 
step in the degradation of 1,25(OH)zD. 
The 24-hydroxylase is composed of an electron-transport 
chain consisting of three proteins - ferredoxin reductase, fer- 
redoxin, and a specific cytochrome P450 - P450cc24 
(CYP24) [3]. With the purification and cloning of CYP24 
[6,7], it has been possible to study the hormonal regulation 
of the 24-hydroxylase in intestinal [8], renal [9], and bone cells 
[10]. In osteoblastic ceils, we have found that the 24-hydrox- 
ylase is induced by 1,25(OH)2D and that this induction is 
potentiated by parathyroid hormone (PTH) [10]. 
Insulin and insulin deficiency (diabetes) have significant ef- 
fects on calcium and vitamin D metabolism, including loss of 
bone mineral [11]. We have previously shown that diabetes 
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The UMR-106 cell line was obtained from the American Type 
Culture Collection. This cell line is a cloned derivative of a transplant- 
able rat osteogenic sarcoma [14]. Cells were cultured in T25 flasks 
with Dulbecco's modified Eagle's medium containing 10% fetal bovine 
serum. Cells reached confluence in 3-5 days and were used within 30 
passages of receipt as previously described [10]. 
To study the effects of hormones, confluent cells were deprived of 
serum for 24 h. Cells were then treated with hormones for 0-36 h, 
depending on the experiment. The 1,25(OH)2D was a kind gift from 
Dr. Milan Uskokovic (Hoffmann-LaRoche, Nutley, NJ), and the 
PTH was rat PTH (1-34) from Bachem (Torrance, CA). Insulin 
used was either purified from bovine pancreas (Sigma, St. Louis, 
MO) or was human recombinant insulin (Calbiochem, San Diego, 
CA). Insulin-like growth factor 1 (IGF-1) used was recombinant hu- 
man IGF-1 (Calbiochem, San Diego, CA). At the end of the experi- 
ment, cells were washed and stored frozen until isolation of total 
RNA using RNAzol (Tel-Test, Inc., Friendswood, TX). 
The CYP24 mRNA levels were measured by dot blot as previously 
described [10]. The full length clone for rat CYP24 (p108, 3.2 kb) [7], 
kindly supplied by Drs. Y. Ohyama nd K. Okuda (Hiroshima Uni- 
versity School of Dentistry, Hiroshima, Japan), was used to generate 
the radiolabeled probe. Some dot blots were stripped and rehybridized 
with a probe for beta-actin (Oncor, Inc., Gaithersburg, MD). This 
checked for uniformity of sample loading and the specificity of the 
response to 1,25(OH)2D. Based on actin rehybridization, sample load- 
ing was quite uniform. Therefore, data were routinely normalized to 
the amount of total RNA applied, which was determined spectropho- 
tometrically [10]. 
24-Hydroxylase activity was measured using radiolabeled 
25(OH)D3 as a substrate, as previously described [10]. Briefly, cells 
were cultured to confluence in T75 flasks, washed twice with serum- 
free medium, and then pre-incubated for 1 h in serum-free medium. 
Cells were then incubated with 50 nM radiolabeled 25(OH)D3 for 1 h. 
After lipid extraction, the tritiated vitamin D products were partially 
0014-5793/96/$12.00 © 1996 Federation of European Biochemical Societies. All rights reserved. 
PH S00 1 4-579 3(96)008 56-3 
78 
purified using silica and C18 Sep-paks and then separated out by 
HPLC. HPLC was performed using a Zorbax-Sil column (0.5)<25 
cm) and a solvent system of hexane:methylene chloride:methanol 
(77:17.25:5.75). 
Data are reported as the mean _+ S.E.M. of the indicated number of 
flasks. The two-tailed Student's t-test was used to determine signifi- 
cance, and P < 0.05 was considered significant. 
3. Results 
We studied the effect of insulin on the induction of CYP24 
mRNA by 1,25(OH)2D and PTH (Fig. 1). Cells were incu- 
bated with hormones for 6 h, and mRNA levels for individual 
flasks were determined by dot blot (Fig. 1A). In the absence 
of insulin (control), 1,25(OH)2D (I00 nM) alone slightly in- 
creased CYP24 mRNA levels. PTH (25 nM) alone had no 
effect, but PTH markedly increased CYP24 mRNA levels in 
the presence of 1,25(OH)2D, as previously reported [10]. In 
the presence of 10 nM insulin (insulin-treated), the effect of 
1,25(OH)2D on mRNA levels was significantly increased com- 
pared to 1,25(OH)2D alone. In addition, insulin potentiated 
the action of PTH in the presence of 1,25(OH)~D by about 3- 
fold. Insulin and insulin plus PTH had no effect in the absence 
of 1,25(OH)2D. A dot blot of the pooled samples for each 
experimental condition is shown in Fig. lB. A Northern blot 
of pooled samples howed a single band at 3.6 kb, regardless 
of hormone treatment (Fig. 1C). This is very close to the 
previously reported size of the CYP24 transcript in renal cells 
[9]. Insulin and PTH had no effect on beta-actin mRNA levels 
in the same studies (data not shown). 
Because of the large increase, we further characterized the 
effect of insulin on PTH action with regard to CYP24 mRNA 
levels. All experiments were performed in the presence of 100 
nM 1,25(OH)2D, since 1,25(OH)2D was needed to observe an 
effect of insulin. From 3 to 36 h after addition, insulin (10 
nM) significantly increased CYP24 mRNA levels over those 
seen with PTH (25 nM) alone (Fig. 2). At its maximum, 
CYP24 mRNA levels were over 3-fold higher in the presence 
of insulin compared to PTH alone. Insulin increased CYP24 
mRNA levels in a dose-dependent fashion over the concentra- 
tion range of 0.10-100 nM after 3 h (Fig. 3). Finally, insulin 
significantly increased CYP24 mRNA levels in the concentra- 
tion range of 0.25-25 nM PTH (Fig. 4). Insulin (10 nM) 
increased the maximal response to PTH by about 3-fold after 
3 h. The half-maximal effective concentration (ECs0) of PTH 
was about 1 nM in both the absence and presence of insulin. 
Since insulin had markedly potentiated CYP24 mRNA lev- 
els by 3 h (Fig. 2), the effect of insulin on 24-hydroxylase 
activity was determined after the same time interval (Table 
Table 1 
Effect of hormones on 24-hydroxylase activity 
Condition 24-Hydroxylase activity (pmol/h 
per mg protein) 
Control 1.97 + 0.15 
1,25(OH)2D 2.10 + 0.16 
1,25(OH)2D+insulin 1.91 + 0.11 
1,25(OH)2D+PTH 6.60 + 0.99 a 
1,25(OH)2D+PTH+insulin 12.4 + 1.6 b 
Table entries are the mean + S.E.M. of 4 individual f asks. Cells were 
treated with I0 nM insulin, I00 nM 1,25(OH)2D, and/or 25 nM PTH 
for 3 h. 
aSignificantly different from control (P < 0.05, t-test). 
bSignificantly different from 1,25(OH)~D+PTH (P < 0.05, t-test). 
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Fig. 1. Effect of insulin on the action of PTH and 1,25(OH)2D. 
Flasks of UMR cells were treated with PTH and/or 1,25(OH)2D 
(1,25D) in the presence or absence of insulin for 6 h. Hormone con- 
centrations were 25 nM PTH, 100 nM 1,25(OH)2D, and 10 nM in- 
sulin. CYP24 mRNA levels were quantitated by dot blot. (A) 
Mean + S.E.M. of CYP24 mRNA levels in 4 individual f asks. Insu- 
lin significantly increased the effect of 1,25(OH)2D and 
1,25(OH)2D+PTH (P < 0.05, t-test) but had no effect in the absence 
of 1,25(OH)2D. (B) Dot blot of pooled RNA samples from each ex- 
perimental condition: (1) No hormones; (2) 1,25D alone; (3) PTH 
alone; (4) 1,25D+PTH; (5) insulin alone; (6) 1,25D+insulin; (7) 
PTH+insulin; and (8) 1,25D+PTH+insulin. (C) Northern blot of 
pooled RNA samples. Lanes 1-8 contain RNA from cells incubated 
under the same experimental conditions as (B). Blot was calibrated 
by running standards of known molecular size in one lane (numbers 
on right). 
1). PTH (25 nM) markedly increased 24-hydroxylase activity 
in the presence of 100 nM 1,25(OH)2D. Addition of insulin 
(10 nM) resulted in a further significant increase in activity in 
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Fig. 2. Time course of insulin action. UMR cells were treated with 
PTH (25 nM) in the presence or absence of insulin (10 nM) for the 
indicated period of time. 1,25(OH)2D (100 nM) was present in all 
experiments. CYP24 mRNA levels were quantitated by dot blot. 
Data points are the mean + S.E.M. of 4 flasks. Insulin significantly 
increased the effect of PTH at all time points (P < 0.05, t-test). 
the presence of 1,25(OH)2D and PTH. 1,25(OH)2D alone and 
1,25(OH)2D+insulin had no measurable effect on hydroxylase 
activity. This lack of effect may be due to the short incubation 
time with hormones (3 h). 
Since IGF-1 is related to insulin with regard to mechanism 
of action, the capacity of IGF-1 to potentiate the action of 
PTH after 3 h was studied. IGF-1 increased CYP24 mRNA 
levels in a dose-dependent fashion in the presence of 25 nM 
PTH and 100 nM 1,25(OH)2D (Fig. 5). IGF-1 concentrations 
as low as 0.1 nM were effective. This is similar to the potency 
of insulin in this system (Fig. 3), suggesting that insulin and 
IGF-1 are working through their own specific receptors. The 
effects of IGF-1 and insulin on CYP24 mRNA levels were not 
additive (data not shown), suggesting that their signal trans- 
duction pathways may converge distal to their receptors. 
To determine if the action of insulin was dependent on 
protein synthesis, experiments were performed with cyclohex- 
imide (Table 2). Cycloheximide (30 gg/ml) had no effect on 
the action of 1,25(OH)2D alone or 1,25(OH)2D+PTH. How- 
ever, the action of insulin in combination with 1,25(OH)2D 
and PTH was significantly inhibited by 43% in the presence of 
cycloheximide. Thus, insulin in combination with 1,25(OH)2D 
and PTH produced an increase in CYP24 mRNA which was 
partially dependent on new protein synthesis. 
Table 2 
Effect of cycloheximide on hormone action 
Agonist CYP24 mRNA (OD/mg) 
-Cycloheximide +Cycloheximide 
Control 0 0 
1,25(OH)2D 52 + 6 144 + 3 
1,25(OH)2D+PTH 176 + 29 175 + 7 
1,25(OH)2D+PTH+insulin 512 + 16 294 + 20 ~ 
Table entries are the mean +_ S.E.M. of 5 flasks. Cells were preincu- 
bated with 1,25(OH)2D for 3 h. PTH and insulin were then added, 
and cells were incubated for an additional 3 h in the presence or 
absence of cycloheximide. Control cells were incubated for 6 h in 
the absence of hormones. Concentrations were 30 I.tg/ml cyclohexi- 
mide, 25 nM PTH, 100 nM 1,25(OH)2D, and 10 nM insulin. 
%ignificantly different from minus cycloheximide (P < 0.05, t-test). 
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Fig. 3. Dose response of insulin action. UMR cells were treated 
with the indicated concentration of insulin for 3 h. PTH (25 nM) 
and 1,25(OH)2D (100 nM) were present in all experiments. CYP24 
mRNA levels were quantitated by dot blot. Data points are the 
mean + S.E.M. of 4 flasks. Insulin had a significant effect at concen- 
trations of 0.1-100 nM (P < 0.05, t-test). 
4. Discussion 
These studies demonstrate that insulin potentiates the ac- 
tion of PTH with regard to the expression of the 24-hydrox- 
ylase in osteoblastic cells. Insulin markedly increases the ac- 
tion of PTH with regard to both CYP24 mRNA levels (Fig. 1) 
and enzyme activity (Table 1). Insulin also has a small effect 
on the action of 1,25(OH)2D alone. However, the magnitude 
of the effect on 1,25(OH)2D is much smaller than that on 
1,25(OH)2D and PTH combined (Fig. 1). 
Insulin alone has no effect on 24-hydroxylase expression 
(Fig. 1), suggesting that insulin works by enhancing the 
1,25(OH)2D/PTH stimulatory pathway. This is consistent 
with the time course and dose-response tudies. Insulin mag- 
nifies the action of 1,25(OH)2D/PTH without changing the 
time course (Fig. 2). Likewise, insulin alters the maximal re- 
sponse of the UMR cells to PTH without significantly altering 
their sensitivity to PTH (Fig. 4). 
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Fig. 4. Effect of insulin on PTH dose response. UMR ceils were in- 
cubated with the indicated concentration of PTH in the presence or 
absence of 10 nM insulin for 3 h. 1,25(OH)2D (100 nM) was pre- 
sent in all experiments. CYP24 mRNA levels were quantitated by 
dot blot. Data points are the mean + S.E.M. of 4 flasks. Insulin sig- 
nificantly increased the effect of PTH at PTH concentrations of 
0.25~2500 nM (P < 0.05, t-test). 
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Fig. 5. Dose response of IGF-1 action. UMR cells were treated 
with the indicated concentration of IGF-1 for 3 h in the presence of 
PTH (25 nM) and 1,25(OH)2D (100 nM). CYP24 mRNA levels 
were quantitated by dot blot. Data points are the mean + S.E.M. of 
4 flasks. IGF-1 had a significant effect at concentrations of 0.1-10 
nM (P < 0.05, t-test). 
Insulin may act via multiple pathways [15] to potentiate the 
action of 1,25(OH)2D and PTH. Presumably, insulin is acting 
via the insulin receptor which has been characterized in UMR 
cells [16]. Part of the effect of insulin requires new protein 
synthesis while part does not (Table 2). This is in contrast 
to the action of PTH, which does not require new protein 
synthesis. The insulin pathway requiring new protein synthesis 
may involve such things as the induction of immediate arly 
genes or the synthesis of new vitamin D receptors. Insulin and 
PTH increase c-fos mRNA levels in these cells [17], and 
growth factors can increase vitamin D receptor gene expres- 
sion in cultured cells [18]. The component of insulin action 
not requiring protein synthesis may involve phosphorylation 
of existing proteins. Insulin may alter the phosphorylation 
state of proteins uch as the cAMP response lement binding 
protein (CREB) [19], ferredoxin [20], or the vitamin D recep- 
tor [21]. 
Insulin and IGF-1 are associated with bone growth or a 
decreased rate of bone loss [11,22]. The present studies uggest 
several ways by which insulin and IGF-1 may reduce bone 
loss. One possibility is that the stimulation of 24-hydroxylase 
activity in bone cells by insulin and IGF-1 inhibits the action 
of 1,25(OH)2D in bone. It has been suggested that 24-hydro- 
xylation is the first step in the degradation of 1,25(OH)2D by 
target tissues [23,24]. Another mechanism by which insulin 
could increase bone density involves the production of 
24,25(OH)2D from circulating 25(OH)D by bone. 
24,25(OH)2D has been reported to be essential for bone for- 
mation [25]. 
It is of interest hat insulin decreases 24-hydroxylase activ- 
ity in the kidney [12] but increases it in bone cells(Table 1) in 
the presence of PTH. This may reflect the fact that a major 
function of the 24-hydroxylase (and the 1-hydroxylase) in the 
kidney is to hydroxylate 25(OH)D to 24,25(OH)2D (and 
1,25(OH)2D). In bone, the major function of the 24-hydrox- 
ylase may be to inactivate 1,25(OH)2D. Thus, from a physio- 
logical standpoint it may be appropriate for insulin, which 
stimulates 1,25(OH)zD production by the kidney, to also in- 
hibit 1,25(OH)2D action in bone via induction of the 24-hy- 
droxylase. On the other hand, lack of insulin (diabetes) could 
result in decreased 24-hydroxylase activity and increased ac- 
tion of 1,25(OH)2D in bone. 
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